関連する実験動画
Updated: Sep 10, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
統合されたin vitro,マイクロアレイ,およびネットワークの薬理学分析により,Vigna unguiculataのマルチターゲットの抗糖尿病能力が明らかになりました
Haseeba Sardar1, Fatima Noor2, Syed Muhammad Mukarram Shah3
1Department of Pharmacy, Abdul Wali Khan University, Mardan - Pakistan.
Drug target insights
|August 27, 2025
まとめ
2型糖尿病 (T2DM) の自然療法として重要な可能性を示しています. ネットワークの薬理学とインビトロ研究により,抗糖尿病特性が確認され,有望な治療薬として示唆されています.
科学分野:
- 薬理学について
- コンピュータ生物学
- エスノボタニー
背景:
- 2型糖尿病 (T2DM) は,世界的な健康上の大きな課題であり,新たな治療戦略が必要である.
- 現在のT2DM治療は限界に直面し,代替的かつ補完的なアプローチへの研究を推進しています.
研究 の 目的:
- 統合されたネットワーク薬理学と in silico/in vitroアプローチを用いて,Vigna unguiculataの抗糖尿病の可能性を調査する.
- T2DM治療に関連するVigna unguiculata内の主要な分子標的と生物活性化合物を特定する.
主な方法:
- ヴィグナ・アンギキュラタの水アルコール抽出と分化
- インビトロ酵素阻害試験 (α-アミラーゼ,α-グルコシダゼ,アルドース還元酵素)
- 標的の特定 (STITCH,SwissTargetPrediction),PPI分析,分子ドッキング,分子ダイナミクスシミュレーションのためのネットワーク薬理学.
主要な成果:
- Vigna unguiculataの抽出物は,α-アミラーゼ,α-グルコシダゼ,アルドーゼ還元酵素を抑制する有意な作用を示した.
- ネットワーク分析により,糖尿病に関連する重要な遺伝子 (EGFR,PTGS2,TLR4) が特定されました.
- 分子ドッキングとシミュレーションでは,スティグマストロール,ルテオリン,クエルセチンのような化合物が標的タンパク質と強い結合関係を明らかにした.
結論:
- ヴィグナ・アンギキュラタは天然の抗糖尿病剤の源として相当な期待を示している.
- この研究は,T2DM管理のためのVigna unguiculataのさらなる調査と臨床試験のための強力な科学的根拠を提供します.
さらに関連する動画
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Diabetes: Management and Pharmacotherapy
362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K

